Rchr
J-GLOBAL ID:201901019722774068
Update date: Oct. 08, 2024
Toshifumi Yamaguchi
Toshifumi Yamaguchi
Affiliation and department:
Research field (1):
Tumor diagnostics and therapeutics
Research theme for competitive and other funds (1):
- 2017 - 2020 Regulatory effects of IL-6 by Kampo preparation for cancer chemotherapy and cachexia
Papers (46):
-
Motoo Nomura, Toshifumi Yamaguchi, Keisho Chin, Shinji Hato, Ken Kato, Eishi Baba, Hisahiro Matsubara, Hidenori Mukaida, Takako Yoshii, Masahiro Tsuda, et al. Phase II Trial of Adjuvant S-1 Following Neoadjuvant Chemotherapy and Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: The PIECE Trial. Annals of surgical oncology. 2024
-
Atsuo Takashima, Megumi Ishiguro, Keita Sasaki, Ryunosuke Machida, Fumio Nagashima, Jun Imaizumi, Tetsuya Hamaguchi, Yoshiyuki Yamamoto, Toshiki Masuishi, Masako Asayama, et al. Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group. Japanese journal of clinical oncology. 2024. 54. 10. 1107-1114
-
Toshifumi Yamaguchi, Koshi Kumagai, Shusuke Yagi, Takashi Nomura, Kengo Nagashima, Masaya Watanabe, Rie Makuuchi, Kentaro Kawakami, Tomohiro Matsushima, Shigenori Kadowaki, et al. Efficacy of chemotherapy for patients with gastric cancer with early recurrence during or after adjuvant chemotherapy with S-1 alone: a multicenter retrospective study. Scientific Reports. 2024. 14. 1
-
Yoshiyuki Yamamoto, Hiroki Yukami, Tatsuro Yamaguchi, Hisatsugu Ohori, Sachiko Nagasu, Yoshinori Kagawa, Naotoshi Sugimoto, Hiromichi Sonoda, Kentaro Yamazaki, Atsuo Takashima, et al. Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study. International journal of clinical oncology. 2024
-
Kenro Hirata, Kayo Yoshida, Chikatoshi Katada, Akinori Watanabe, Takahiro Tsushima, Toshifumi Yamaguchi, Sachiko Yamamoto, Hideki Ishikawa, Yasunori Sato, Chiyo K Imamura, et al. Definitive chemoradiotherapy with paclitaxel for locally advanced esophageal squamous cell carcinoma in older patients (PARADISE-1): a phase I trial. BMC cancer. 2024. 24. 1. 873-873
more...
MISC (41):
-
大鶴 徹, 山口 敏史, 武本 憲彦, 坂井 大介, 佐藤 太郎, 池田 公史. Minimal/molecular residual disease(MRD). 腫瘍内科. 2022. 29. 3. 371-376
-
石塚保亘, 山口敏史, 佐藤太郎. Regimens of Anti-EGFR and HER2 Antibody Drugs. 臨床消化器内科. 2022. 37. 11
-
山口 敏史. 進展胃癌に対する薬物治療はこれからどう変わるか? 胃がん術後早期再発に対するラムシルマブ+イリノテカンの第II相試験(A phase II trial of ramucirumab plus irinotecan for patients with early relapced gastric cancer). 日本胃癌学会総会記事. 2021. 93回. 210-210
-
児玉紘幸, 山口敏史, 石塚保亘, 宮本敬大, 寺澤哲志, 島本福太郎, 濱元宏喜, 大住渉, 山本誠士, 田中慶太朗, et al. Association between T stage and tumor budding grade as prognostic factors for recurrence in pathological stage II colon cancer, retrospectively. 日本消化管学会雑誌. 2021. 5. Supplement
-
村地 康, 坂井 大介, 山口 敏史, 佐藤 太郎. 消化器癌化学療法の進歩と課題 レゴラフェニブで治療した進行・再発結腸直腸癌患者におけるサルコペニアの影響. 日本消化器病学会近畿支部例会プログラム・抄録集. 2020. 113回. 52-52
more...
Education (2):
- - 2018 大阪医科大学大学院
- - 2008 Kawasaki Medical School
Professional career (1):
Work history (10):
- 2024/05 - 現在 Osaka Medical and Pharmaceutical University Cancer Chemotherapy Center
- 2023/10 - 2024/04 Osaka Medical and Pharmaceutical University
- 2022/03 - 2023/09 大阪医科薬科大学 化学療法センター 講師(准)、化学療法センター副センター長
- 2021/04 - 2022/03 大阪大学医学部附属病院 消化器外科 助教
- 2020/04 - 2021/03 大阪大学医学部附属病院 先進癌薬物療法開発学寄付講座 助教
- 2017/03 - 2020/04 Osaka Medical and Pharmaceutical University
- 2014/04 - 2017/03 国立がん研究センター中央病院 固形腫瘍レジデント
- 2011/04 - 2014/03 春秋会 城山病院 消化器内科 医員
- 2010/04 - 2011/03 大阪医科大学 消化器内科レジデント
- 2008/04 - 2010/03 川崎医科大学附属病院 初期研修医
Show all
Committee career (7):
Awards (3):
- 2024/09 - 日本がんチーム医療研究会 優秀演題賞
- 2018/03 - 大阪難病研究財団 医学研究助成金
- 2013/09 - 第93回日本消化器病学会 Yong investigator aword
Return to Previous Page